Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apomate may predict patient's chemotherapy response:

This article was originally published in Clinica

Executive Summary

North American Scientific (NAS) has filed an application with the US FDA for permission to continue with studies to evaluate its nuclear imaging agent, Apomate - technetium-labelled annexin V - for assessing a patient's response to chemotherapy. Apomate, developed by NAS' subsidiary Theseus Imaging, targets phosphatidylserine, which is released during cell death. The Chatsworth, California company is currently conducting clinical trials of Apomate for imaging acute myocardial infarction and cardiac transplant rejection.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel